JP2019536461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536461A5 JP2019536461A5 JP2019530100A JP2019530100A JP2019536461A5 JP 2019536461 A5 JP2019536461 A5 JP 2019536461A5 JP 2019530100 A JP2019530100 A JP 2019530100A JP 2019530100 A JP2019530100 A JP 2019530100A JP 2019536461 A5 JP2019536461 A5 JP 2019536461A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- cells
- recombinant
- incubation
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 37
- 210000001744 T-lymphocyte Anatomy 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 17
- 238000011534 incubation Methods 0.000 claims 13
- 108010002350 Interleukin-2 Proteins 0.000 claims 7
- 102000000588 Interleukin-2 Human genes 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 102000003812 Interleukin-15 Human genes 0.000 claims 5
- 108090000172 Interleukin-15 Proteins 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 102000006306 Antigen Receptors Human genes 0.000 claims 4
- 108010083359 Antigen Receptors Proteins 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 108010029697 CD40 Ligand Proteins 0.000 claims 3
- 102100032937 CD40 ligand Human genes 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000000284 resting effect Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022008417A JP2022058727A (ja) | 2016-12-05 | 2022-01-24 | 養子細胞療法のための操作細胞の産生 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430349P | 2016-12-05 | 2016-12-05 | |
| US62/430,349 | 2016-12-05 | ||
| PCT/US2017/064778 WO2018106732A1 (en) | 2016-12-05 | 2017-12-05 | Production of engineered cells for adoptive cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022008417A Division JP2022058727A (ja) | 2016-12-05 | 2022-01-24 | 養子細胞療法のための操作細胞の産生 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536461A JP2019536461A (ja) | 2019-12-19 |
| JP2019536461A5 true JP2019536461A5 (enExample) | 2021-01-21 |
Family
ID=60935957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530100A Pending JP2019536461A (ja) | 2016-12-05 | 2017-12-05 | 養子細胞療法のための操作細胞の産生 |
| JP2022008417A Pending JP2022058727A (ja) | 2016-12-05 | 2022-01-24 | 養子細胞療法のための操作細胞の産生 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022008417A Pending JP2022058727A (ja) | 2016-12-05 | 2022-01-24 | 養子細胞療法のための操作細胞の産生 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190350978A1 (enExample) |
| EP (1) | EP3548611A1 (enExample) |
| JP (2) | JP2019536461A (enExample) |
| KR (1) | KR20190098747A (enExample) |
| CN (1) | CN110249046A (enExample) |
| AU (1) | AU2017370644A1 (enExample) |
| BR (1) | BR112019011207A2 (enExample) |
| CA (1) | CA3045338A1 (enExample) |
| MA (1) | MA46998A (enExample) |
| MX (1) | MX2019006438A (enExample) |
| WO (1) | WO2018106732A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400115B2 (en) | 2014-04-23 | 2022-08-02 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| KR20180108567A (ko) | 2015-10-22 | 2018-10-04 | 주노 테라퓨틱스 게엠베하 | 형질도입을 위한 방법, 키트, 제제 및 장치 |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019051097A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| WO2020047449A2 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| ES3042082T3 (en) * | 2018-08-31 | 2025-11-18 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020092696A1 (en) * | 2018-10-31 | 2020-05-07 | Musc Foundation For Research Development | Ex vivo activation and expansion of t cells for adoptive cell transfer therapy |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| WO2020102701A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for the manufacture of th1/tc1 phenotype t cells |
| US10918667B2 (en) * | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| EP3917563A4 (en) * | 2019-01-29 | 2022-10-26 | GPB Scientific, Inc. | CELL POPULATIONS WITH IMPROVED MANUFACTURING AND THERAPEUTIC PROPERTIES |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| WO2020210678A1 (en) * | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| SG11202112382WA (en) | 2019-05-07 | 2021-12-30 | Gracell Biotechnologies Shanghai Co Ltd | Engineered immune cell targeting bcma and use thereof |
| KR20220015452A (ko) * | 2019-05-28 | 2022-02-08 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 유전자 변형된 t 세포의 생성 방법 |
| CN114600172A (zh) * | 2019-08-30 | 2022-06-07 | 朱诺治疗学股份有限公司 | 用于将细胞分类的机器学习方法 |
| CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
| KR20220130125A (ko) * | 2020-01-21 | 2022-09-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 동결보존 세포의 조성물 및 방법 |
| TW202140790A (zh) * | 2020-01-22 | 2021-11-01 | 愛爾蘭商佧琺藥業有限公司 | 病毒載體轉導細胞的方法 |
| IL295129A (en) * | 2020-01-30 | 2022-09-01 | Umoja Biopharma Inc | Bispecific transduction enhancer |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| JP2023518395A (ja) * | 2020-03-19 | 2023-05-01 | インテリア セラピューティクス，インコーポレイテッド | 指向性ゲノム編集のための方法及び組成物 |
| US20230138309A1 (en) * | 2020-03-20 | 2023-05-04 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| CN112831525A (zh) * | 2020-10-21 | 2021-05-25 | 东莞清实生物科技有限公司 | 一种简单高效的慢病毒冻存液及其应用 |
| WO2022150731A1 (en) * | 2021-01-11 | 2022-07-14 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| GB202105113D0 (en) * | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| WO2022246041A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions and methods for multivalent surface display on enveloped particles |
| WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| CN113846099B (zh) * | 2021-09-23 | 2022-04-22 | 中国农业科学院兰州兽医研究所 | 用于敲低猪SAMHD1基因表达的siRNA、试剂盒及其应用 |
| WO2023205037A1 (en) * | 2022-04-17 | 2023-10-26 | Biogen Ma Inc. | Methods of delivering nucleotide sequences to cells via simultaneous transduction |
| EP4565265A2 (en) * | 2022-08-04 | 2025-06-11 | Lyell Immunopharma, Inc. | Methods of manufacturing chimeric antigen receptor t cells |
| US20240228959A9 (en) * | 2022-10-10 | 2024-07-11 | Kite Pharma, Inc. | Large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection |
| WO2024243365A2 (en) * | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5565566A (en) | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| DE68918494T2 (de) | 1988-05-17 | 1995-03-23 | Lubrizol Genetics Inc | Pflanzliches Ubiquitinpromotorsystem. |
| US5298508A (en) | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5424297A (en) | 1992-04-27 | 1995-06-13 | University Of Virginia Alumni Patents Foundation | Adenosine dextran conjugates |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| AU6781194A (en) | 1993-05-03 | 1994-11-21 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists |
| US5504090A (en) | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5670501A (en) | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| ATE548351T1 (de) | 1996-01-29 | 2012-03-15 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| DE69605062T2 (de) | 1996-04-24 | 2000-07-13 | Claude Fell | Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut |
| US5786360A (en) | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| WO1998032869A1 (en) | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
| US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| ATE271890T1 (de) | 1998-12-24 | 2004-08-15 | Biosafe Sa | Vorrichtung zur bluttrennung, insbesondere zur konzentrierung von hematopoietischen stammzellen |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6313131B1 (en) | 1999-02-16 | 2001-11-06 | Upsher-Smith Laboratories, Inc. | Method of kidney treatment |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US7078205B2 (en) | 2000-02-17 | 2006-07-18 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| JP4317940B2 (ja) | 2001-08-31 | 2009-08-19 | イミュノコア・リミテッド | 物質 |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| CN101914532A (zh) | 2002-11-22 | 2010-12-15 | 生物智囊团株式会社 | Rna干扰的目标碱基序列的搜索方法 |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| US8865224B2 (en) * | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
| EP1893253B1 (en) | 2005-03-23 | 2010-05-19 | Biosafe S.A. | Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine |
| CN101238218A (zh) * | 2005-05-20 | 2008-08-06 | 维克西斯公司 | 初级细胞的转导 |
| US20080279866A1 (en) * | 2006-08-25 | 2008-11-13 | The Brigham And Women's Hospital, Inc. | Induction of immunosuppression by inhibition of ATM |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| EP3444333A1 (en) | 2009-10-22 | 2019-02-20 | Thomas Jefferson University | Cell-based anti-cancer compositions and methods of making and using the same |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| JP6082997B2 (ja) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| US9149519B2 (en) | 2012-01-17 | 2015-10-06 | New York University | Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| US9371396B2 (en) | 2012-06-15 | 2016-06-21 | Sinomab Bioscience Limited | Anti-CD22 anti-idiotypic antibodies and uses thereof |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| KR20210108497A (ko) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| US9393268B2 (en) | 2013-03-15 | 2016-07-19 | Thomas Jefferson University | Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| WO2015027142A2 (en) * | 2013-08-23 | 2015-02-26 | The Scripps Research Institute | Enhancing efficiency of retroviral transduction of host cells |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| FI3888674T3 (fi) | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| SG11201608557UA (en) * | 2014-04-16 | 2016-11-29 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| WO2015161276A2 (en) | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| US11400115B2 (en) * | 2014-04-23 | 2022-08-02 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| EP4008725A1 (en) | 2014-05-02 | 2022-06-08 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| CN107106611B (zh) | 2014-10-27 | 2021-11-23 | 弗雷德哈钦森癌症研究中心 | 用于提高过继细胞免疫疗法效力的组合物和方法 |
| MA40318A (fr) * | 2014-11-05 | 2017-09-13 | Juno Therapeutics Inc | Procédés de transduction et de traitement de cellules |
| EP3227323B1 (en) * | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| GB201503500D0 (en) * | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| EP3274453B1 (en) * | 2015-03-26 | 2021-01-27 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
| SG10202104509PA (en) * | 2016-03-19 | 2021-06-29 | Exuma Biotech Corp | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
-
2017
- 2017-12-05 CN CN201780085444.1A patent/CN110249046A/zh active Pending
- 2017-12-05 MA MA046998A patent/MA46998A/fr unknown
- 2017-12-05 EP EP17825665.7A patent/EP3548611A1/en not_active Withdrawn
- 2017-12-05 MX MX2019006438A patent/MX2019006438A/es unknown
- 2017-12-05 JP JP2019530100A patent/JP2019536461A/ja active Pending
- 2017-12-05 AU AU2017370644A patent/AU2017370644A1/en not_active Abandoned
- 2017-12-05 KR KR1020197019497A patent/KR20190098747A/ko not_active Ceased
- 2017-12-05 US US16/465,140 patent/US20190350978A1/en not_active Abandoned
- 2017-12-05 BR BR112019011207A patent/BR112019011207A2/pt not_active IP Right Cessation
- 2017-12-05 CA CA3045338A patent/CA3045338A1/en active Pending
- 2017-12-05 WO PCT/US2017/064778 patent/WO2018106732A1/en not_active Ceased
-
2022
- 2022-01-24 JP JP2022008417A patent/JP2022058727A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536461A5 (enExample) | ||
| Maldini et al. | CAR T cells for infection, autoimmunity and allotransplantation | |
| US20250002850A1 (en) | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors | |
| Cerwenka et al. | Natural killer cell memory in infection, inflammation and cancer | |
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| JP6126804B2 (ja) | Ｔ細胞受容体のクローニング方法 | |
| CN107002039B (zh) | 使用t细胞用于培养自然杀伤细胞的方法 | |
| JP2025031794A5 (enExample) | ||
| CN111566201A (zh) | 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法 | |
| RU2018136607A (ru) | Способы и составы для производства лимфоцитов и их регулируемого увеличения | |
| JP2016539929A5 (enExample) | ||
| JP2018522072A5 (enExample) | ||
| JP2014526244A5 (enExample) | ||
| CN109121413A (zh) | 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法 | |
| JP2019520823A5 (enExample) | ||
| JP2024086827A5 (enExample) | ||
| JP2013537187A5 (enExample) | ||
| CN116261466A (zh) | 通用抗原特异性t细胞库及其制备和治疗性使用方法 | |
| JP2019522984A5 (enExample) | ||
| US20220056411A1 (en) | Methods for isolating cd8+ selected t cells | |
| KR20250039412A (ko) | T세포 집단을 확장시키는 방법 | |
| JP5911810B2 (ja) | 制御性ｔ細胞の製造方法 | |
| US20210290672A1 (en) | Regulation of tumor-associated t cells | |
| TW202130807A (zh) | 具有ｃｄ４５ｒａ⁺及ｃｃｒ７⁺之細胞表面標誌的t細胞之製造方法 | |
| WO2023044488A1 (en) | Monocyte depletion of t cells populations for t-cell therapy |